Peginterferon α-2a

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Chronic HepatitisHepatitis C

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

Peginterferon α-2a

Bristol-Myers Squibb

Phase 3

42

Spikevax

Moderna

Preclinical

213

COVID-19 Vaccine

Moderna

Preclinical

274

Aldactone

Pfizer

Preclinical

15

Nexavar

Bayer

Preclinical

16

Aquasol E

NNational Eye Institute (NEI)

Preclinical

17

Benadryl

PParkedale

Preclinical

18

Nitrostat

VViatris Specialty LLC

Preclinical

19

Statin

Bristol-Myers Squibb

Preclinical

110

Selenium

SSWOG Cancer Research Network

Preclinical

1Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-194 trials

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04354259·157 enrolled

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

Completed·SStanford University·Phase 2·NCT04331899·120 enrolled

TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Unknown status·UUniversity Health Network, Toronto·Phase 3·NCT04967430·763 enrolled

Show 1 more trial

Interferon Lambda Therapy for COVID-19

Withdrawn·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT04388709

Efficacy and Safety3 trials

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Completed·Bristol-Myers Squibb·Phase 3·NCT01598090·881 enrolled

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed·Bristol-Myers Squibb·Phase 3·NCT01718158·444 enrolled

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Unknown status·EEiger BioPharmaceuticals·Phase 3·NCT05070364·150 enrolled

Chronic Hepatitis3 trials

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Completed·Bristol-Myers Squibb··NCT01525810·218 enrolled

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02765802·33 enrolled

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Completed·Bristol-Myers Squibb·Phase 2·NCT02175966·35 enrolled

Hepatitis C1 trial

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Completed·Bristol-Myers Squibb·Phase 3·NCT01754974·40 enrolled

Tyrosine Kinase Inhibitor1 trial

Malaysia Stop Tyrosine Kinase Inhibitor Trial

Unknown status·MMinistry of Health, Malaysia·Phase 3·NCT02381379·118 enrolled

Details

Drug Info

Related News